富士征：在慢性中心性浆液性脉络膜视网膜病变中对光动力疗法的患病率和预测能力。
Fuji sign: Prevalence and predictive power to photodynamic therapy in chronic central serous chorioretinopathy.
机构信息
Ophthalmology Unit, Hospital Clinico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Ophthalmology Unit, Hospital Clinico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
出版信息
Photodiagnosis Photodyn Ther. 2023 Jun;42:103316. doi: 10.1016/j.pdpdt.2023.103316. Epub 2023 Feb 4.
AIM
To determine the prevalence of Fuji sign in central serous chorioretinopathy (cCSC) patients and its predictive power of good response to photodynamic therapy (PDT).
METHODS
Retrospective study, including 135 eyes of 130 patients diagnosed with cCSC treated with PDT between 2017 and 2021. Optical Coherence Tomography (OCT) images from these patients were compiled and analyzed. The presence of the Fuji sign, an anatomical finding recently described as a predictor of spontaneous resolution of the subretinal fluid (SRF) in cCSC, as assessed in basal images and the maximum height of SRF pre- and post-PDT OCT was measured.
RESULTS
Mean age was 56.6 years, 69.4% were men and the percentage of partial or complete resolution of the SRF after PDT was 75.55%. Only 8.9% of patients (12/135) had positive Fuji sign at baseline OCT. Among them, 50% (6/12) presented a complete response to the PDT (pre-PDT SRF: 109.00 (29.61) µm), 8.3% (1/12) had a partial resolution of the SRF (127 µm to 66 µm) and 41.6% (5/12) did not respond to PDT (pre-PDT SRF: 71.00 (22.82) µm, post-PDT SRF: 83.60 (36.13) µm).
CONCLUSIONS
Fuji sign has a low prevalence in cCSC and its presence is not associated with a good response to PDT.
目的
确定中央性浆液性脉络膜视网膜病变（cCSC）患者富士征的患病率及其对光动力疗法（PDT）良好反应的预测能力。
方法
回顾性研究，纳入 2017 年至 2021 年间接受 PDT 治疗的 130 例 cCSC 患者的 135 只眼。对这些患者的光学相干断层扫描（OCT）图像进行编译和分析。评估基础图像和 PDT 前后 OCT 中 SRF 的最大高度中是否存在富士征，富士征是最近描述的 cCSC 中预测 SRF 自发消退的一种解剖学发现。
结果
平均年龄为 56.6 岁，69.4%为男性，PDT 后 SRF 部分或完全消退的比例为 75.55%。仅 8.9%（12/135）的患者在基线 OCT 中出现阳性富士征。其中，50%（6/12）对 PDT 完全有反应（PDT 前 SRF：109.00（29.61）µm），8.3%（1/12）SRF 部分缓解（127µm 至 66µm），41.6%（5/12）对 PDT 无反应（PDT 前 SRF：71.00（22.82）µm，PDT 后 SRF：83.60（36.13）µm）。
结论
富士征在 cCSC 中的患病率较低，其存在与 PDT 良好反应无关。
Zotero 插件